Lilly Arxxant for diabetic neuropathy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NDA for Lilly's protein kinase C inhibitor ruboxistaurin for treatment of diabetic peripheral neuropathy is slated for the second half of 2005, the company says during an April 18 earnings call. The firm is proposing the trade name Arxxant...